CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancerLorenzo Castagnoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Serenella M. Pupa(Fondazione IRCCS Istituto Nazionale dei Tumori)Journal of Experimental & Clinical Cancer ResearchJanuary 20, 202510.1186/s13046-025-03276-zCited by 11SaveCiteExport RISWatch citationsRelated PapersWNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer|Oncogene|2019|185Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer|Cellular Oncology|2023|21